SCISpinal cord stimulation is one of the most exciting — and most confusing — areas of SCI research. The term covers two related but distinct technologies: epidural stimulation for motor recovery and spinal cord stimulation for pain management. Same general hardware, different purposes, different evidence, different access pathways.
Two Different Things
Epidural electrical stimulation (EES) for motor recovery — Electrodes placed on the dorsal surface of the spinal cord deliver continuous or patterned electrical stimulation to lumbosacral circuits, enabling voluntary movement and standing/walking in people with severe or complete paralysis. This is the technology making international headlines. It is still largely experimental and available primarily through clinical trials.
Spinal cord stimulation (SCS) for pain — Electrodes placed in the epidural space deliver stimulation that modulates pain signals through the dorsal columns. This is an established, FDA-cleared medical device therapy used for chronic pain — including SCI neuropathic pain. It is clinically available and covered by most insurance with appropriate documentation.
Epidural Stimulation for Motor Recovery
The story of epidural stimulation for SCI motor recovery begins with a discovery that upended decades of dogma: the spinal cord below a complete injury isn't simply dead. It retains neural circuits — called central pattern generators — that, when activated by electrical stimulation, can produce coordinated movement.
A series of landmark studies beginning in 2011 and accelerating through 2025 demonstrated that people with clinically complete SCI could stand, step, and in some cases walk independently when epidural stimulation was combined with intensive rehabilitation. This shocked the neuroscience community and reframed the fundamental understanding of spinal cord biology.
How Epidural Stimulation Works
Electrodes implanted in the epidural space (between the vertebrae and the spinal cord) deliver carefully calibrated electrical current to the lumbosacral spinal cord. This stimulation appears to:
- Increase the excitability of motor circuits below the injury, allowing voluntary activation of muscles that couldn't be voluntarily activated before
- Activate central pattern generators that coordinate stepping movements
- Provide a "carrier signal" that amplifies residual signals crossing the injury site — even in so-called complete injuries
The key insight is that the stimulation doesn't bypass the injury — it changes the state of the circuits below the injury, making them more responsive to whatever signals are getting through, however faint.
What Results Actually Look Like
The research results are real and remarkable — but require careful interpretation.
What has been demonstrated:
- Voluntary leg movements and standing in people with complete thoracic SCI
- Supervised and in some cases independent walking with a walker
- Improvements in bladder, bowel, and sexual function
- Cardiovascular improvements — better blood pressure regulation, improved cardiac function
- Reduction in spasticity
- Improvements in pain
What results typically require:
- Months of intensive, daily rehabilitation alongside the stimulation — the stimulation alone doesn't produce recovery; it's the combination of stimulation + activity that drives neuroplasticity
- Ongoing stimulation — most gains depend on the stimulator being active; though there is evidence of some carry-over neuroplastic change with sustained intensive rehabilitation
A 2025 case series: Three participants with complete thoracic SCIs received EES implants combined with 7 months of daily robotic and overground gait training. All three showed improvements in walking measures, trunk assessment, sit-to-stand, and 2-minute walk test. A separate 2025 study demonstrated independent walking with a walker within 3 months for a lower thoracic injury — previously thought outside the range of benefit.
Who Qualifies for Epidural Stimulation Research Programs
Most EES for motor recovery is conducted through research protocols, not as clinical care. Typical inclusion criteria for ongoing trials:
- Traumatic SCI (some trials include non-traumatic)
- At least 12–24 months post-injury (most trials; some are now studying subacute intervention)
- Medically stable
- Committed to the intensive rehabilitation component (often 5 days/week for months)
- Age requirements vary by trial
- Injury level varies — most trials have studied thoracic injuries; newer trials are expanding to cervical and lower lumbar
The injury completeness requirement has loosened significantly — early trials focused on complete (AIS A/B) injuries; many current trials include AIS C and D.
How to Access Epidural Stimulation
Clinical trials: Search clinicaltrials.gov for "epidural stimulation spinal cord injury." Filter by recruiting status and location. Major centers running active trials include University of Louisville, Mayo Clinic, UCSF, and international programs in Europe and Asia.
Established research programs: The Reeve Foundation maintains a list of research programs. Craig Hospital, Kessler Foundation, and Shepherd Center all have active neuromodulation research programs.
Insurance coverage: Currently, EES specifically for motor recovery is not covered by insurance as a clinical indication — it's research. Some centers offer it through trials with no patient cost; others have costs. Ask explicitly.
Spinal Cord Stimulation for Pain: The Clinical Option Available Now
Traditional SCS for pain management is a different, established medical procedure that's been used since the 1960s. It's FDA-cleared for chronic pain and covered by most insurance (with documentation of failed conservative treatment).
How it works for pain: Low-level electrical stimulation applied to the dorsal columns modulates pain signal transmission. The original "paresthesia-based" SCS creates a tingling sensation that replaces pain. Newer "sub-perception" SCS (high-frequency, burst patterns) works without paresthesia and has better evidence for some pain types.
Evidence for SCI pain: SCS has documented efficacy for at-level neuropathic pain — pain at the zone of injury. Evidence for below-level pain is more mixed. Results are highly individual — some people get dramatic relief, others get minimal benefit. A trial stimulation period (external stimulator before permanent implant) allows you to assess benefit before committing.
Process: Typically requires referral to a pain management specialist who implants SCS devices, documentation of failed conservative treatments, and a psychological evaluation. The trial period lasts 5–7 days. If successful (generally defined as ≥50% pain relief), permanent implant follows.
Stimulation Waveforms (Therapy Types)
"Spinal cord stimulator" isn't one thing — modern systems offer several stimulation styles, and many can mix them. The differences are a major part of what separates the companies below.
| Therapy type | How it works | Notes & trade-offs |
|---|---|---|
| Traditional / tonic | Steady low-frequency pulses (≈10–150 Hz) that replace pain with a tingling sensation (paresthesia). | The original approach; useful for confirming the stimulation covers your pain area. Some people dislike the tingling, and it can shift with posture. |
| High-frequency 10 kHz | Very fast pulses that relieve pain without tingling ("paresthesia-free"). | Strong trial data in back/leg pain (pioneered by Nevro). Higher energy use; some studies report higher explant rates than older systems. |
| Burst | Clustered pulse "bursts" that mimic the brain's natural firing patterns; usually paresthesia-free. | Often well tolerated and may help some who didn't respond to tonic stimulation (Abbott's BurstDR). |
| Closed-loop (ECAP) | The device measures the spinal cord's response to each pulse and auto-adjusts in real time as you move, breathe, or change position. | The newest paradigm (Saluda Evoke; Medtronic Inceptiv). Aims for more consistent dosing and less manual tuning. |
| DRG stimulation | Targets the dorsal root ganglion — a focused relay for a specific body region — rather than the whole cord. | Especially effective for focal pain (e.g., CRPS, foot/groin); outperformed tonic SCS for CRPS in a randomized trial. Requires extra implant skill. |
| High-density / sub-perception | Programming variations that deliver relief below the tingling threshold. | Often available within multi-waveform systems as another tool to try. |
→ Survey: waveform choices, batteries & reasons for explant
The Devices & Their Makers
Here is the field of major manufacturers, what each makes, and the honest strengths and trade-offs of their approach — with links to verify current details. (Approvals and company ownership are shifting in 2025–2026; confirm specifics with your physician.)
Medtronic
Systems & technology. Inceptiv™ (closed-loop, ECAP-sensing; FDA-approved 2024), Intellis™ (rechargeable), and Vanta™ (non-rechargeable, long battery life). Broad lead options and a large clinical/support footprint.
Strengths
- Closed-loop self-adjusting therapy (Inceptiv)
- Strong full-body MRI access claims
- Huge support infrastructure and clinician familiarity
- Both rechargeable and primary-cell options
Trade-offs
- A large, established company — less nimble than startups
- Closed-loop is newer; long-term comparative data still maturing
Boston Scientific
Systems & technology. WaveWriter™ Alpha multi-waveform systems (combine and even simultaneously deliver tonic, burst, and high-frequency); Cartesia™ directional leads. FDA-expanded for non-surgical back pain. Acquiring Nalu Medical (2025).
Strengths
- Multi-waveform flexibility — can mix therapies to find what works
- Directional leads for precise targeting
- Expanded approvals (incl. non-surgical back pain)
- Robust programming options
Trade-offs
- Many options can mean more programming complexity
- Newer/acquired tech still being integrated
Abbott
Systems & technology. Proclaim™ XR/Plus with proprietary BurstDR™ stimulation; Eterna™ (rechargeable); and Proclaim™ DRG — the leading dorsal-root-ganglion system for focal pain. Long battery life and Apple-device control.
Strengths
- BurstDR — distinctive, often well-tolerated waveform
- DRG stimulation for focal/regional pain (a real differentiator)
- Long-lived batteries; low-recharge or no-recharge options
- Familiar smart-device interface
Trade-offs
- A 2025 connectivity (Bluetooth) device advisory underscores the care needed with connected controllers
- DRG implantation needs added operator skill
Nevro
Systems & technology. Senza® / HFX™ platform built around 10 kHz high-frequency, paresthesia-free therapy; HFX iQ™ adds AI-assisted programming. Notable FDA approval for painful diabetic neuropathy.
Strengths
- Pioneered paresthesia-free 10 kHz therapy with strong RCT data in back/leg pain
- Dedicated diabetic-neuropathy indication
- Data-driven, AI-assisted programming aimed at fewer visits
Trade-offs
- 10 kHz uses more energy (more frequent recharging)
- Some studies report higher explant rates for 10 kHz
- Single-paradigm focus vs. multi-waveform rivals
- Ownership transition underway
Saluda Medical
Systems & technology. Evoke® — the flagship closed-loop system. It records the cord's evoked response (ECAP) thousands of times per second and adjusts each pulse in real time; the Smart Loop platform and EVA automated programming (2025) extend this.
Strengths
- True real-time closed-loop control — adapts as you move
- Long-term RCT (Evoke) showed durable benefit in back/leg pain
- Reduces manual reprogramming burden
- Biomarker/data-rich approach
Trade-offs
- Newer, smaller company than the big three
- Closed-loop is sophisticated — fit and counseling matter
- Long-term SCI-specific data, like all systems, is limited
Nalu Medical
Systems & technology. A miniaturized, battery-free implanted pulse generator powered by a small externally worn Therapy Disc — one of the smallest IPGs available, used for both SCS and peripheral nerve stimulation.
Strengths
- Very small implant — no internal battery to replace
- Wearable powers and controls the device
- Good fit for peripheral nerve targets
Trade-offs
- Requires wearing the external Therapy Disc during therapy
- Smaller track record; now integrating into Boston Scientific
Biotronik
Systems & technology. Prospera™ SCS (FDA-approved 2023) featuring multiphase stimulation and a 'proactive care' model with remote monitoring and objective data follow-up for chronic trunk/limb pain.
Strengths
- Multiphase stimulation paradigm
- Built-in remote monitoring / proactive follow-up
- Established cardiac-device engineering heritage
Trade-offs
- Newer entrant to the US SCS market
- Smaller real-world SCS evidence base so far
Mainstay Medical
Systems & technology. ReActiv8® delivers restorative neurostimulation: rather than masking pain, it stimulates the nerve to the deep multifidus back muscles to help retrain the muscles that stabilize the spine. Aimed at mechanical chronic low-back pain, not central nerve pain.
Strengths
- Targets an underlying cause (muscle control), not just symptoms
- Different tool for a different problem
Trade-offs
- Designed for mechanical back pain — generally not applicable to central SCI nerve pain
- Distinct indication from the pain stimulators above
The Frontier: Stimulation to Restore Function
Everything above is about controlling pain. But one of the most exciting areas in all of SCI research uses related technology for a completely different goal — restoring movement and lost body functions. This is worth understanding clearly, and worth distinguishing from pain stimulators: the targets, devices, and evidence are different.
By delivering precisely targeted stimulation to the spinal cord below the injury (often paired with intensive activity-based training), researchers have helped people with chronic, even complete, paralysis re-activate muscles and regain function that was thought permanently lost. The same approach is being explored for blood-pressure control, bladder, trunk stability, and spasticity.
ONWARD Medical — ARC-EX®
Systems & technology. ARC-EX delivers programmed electrical stimulation through electrodes placed on the skin of the neck — no surgery. In the Up-LIFT pivotal trial (published in Nature Medicine, 2024) in chronic incomplete tetraplegia, ~90% of participants improved upper-limb strength or function, used alongside rehabilitation. It received FDA de novo clearance in December 2024 — the first non-invasive SCS approved for SCI — and was named a TIME Best Invention of 2024. Clinic use is approved, with home use anticipated.
Strengths
- Non-invasive — no implant or surgery
- FDA-cleared with a published pivotal trial
- Improves hand/arm strength and sensation even years after injury
- Designed to amplify the gains from rehab/training
Trade-offs
- Works with — not instead of — active rehabilitation
- Pivotal evidence is for incomplete cervical (hand/arm) injuries; benefit varies by person
- A newer therapy still rolling out to centers
ONWARD Medical — ARC-IM™ & ARC-BCI™
Systems & technology. ARC-IM is an implanted stimulator with a lead designed specifically for SCI, placed at the injury site for greater precision. It has earned FDA Breakthrough Device designations across multiple goals — restoring leg movement, normalizing blood pressure and trunk stability, bladder control, and reducing spasticity. ARC-BCI pairs ARC-IM with a brain–computer interface — the 'digital bridge' that lets thoughts drive stimulation, demonstrated in research enabling a paralyzed participant to walk again.
Strengths
- Implanted precision for targeted function
- Breakthrough designations for movement, blood pressure, bladder, spasticity
- BCI 'digital bridge' represents genuine cutting-edge progress
Trade-offs
- Investigational — not yet approved for general use
- Available only via clinical studies for now
- Implant-based, with the considerations that brings
Much of this traces to teams such as .NeuroRestore (Grégoire Courtine and Jocelyne Bloch, in Switzerland) and collaborators, whose epidural-stimulation and brain–spine-interface studies — published in journals including Nature and Nature Medicine — turned "walking again after paralysis" from a hope into documented cases. The work is early and individualized, and most function-restoration therapy beyond ARC-EX remains investigational, but the trajectory is real and accelerating.
→ ARC-EX FDA clearance (STAT) · How the technology works (IEEE Pulse)
Autonomic Benefits: Beyond Motor and Pain
One of the more surprising findings from EES research has been the extent of autonomic benefits — improvements in systems controlled by the autonomic nervous system:
- Bladder function: Multiple studies show improved voluntary bladder control and reduced catheterization volume during stimulation
- Blood pressure regulation: Better orthostatic blood pressure control, reduced frequency of autonomic dysreflexia
- Sexual function: Improvements in erection and ejaculatory function reported
- Temperature regulation: Some improvements in thermoregulation
These autonomic improvements may be among the most quality-of-life-relevant outcomes for many patients — and they don't require walking to be a meaningful benefit.
Realistic Expectations
The media coverage of epidural stimulation has, predictably, produced both hope and confusion. What you should realistically understand:
This is not a cure. It's a technology that, combined with intensive rehabilitation, can produce meaningful functional recovery. The stimulator needs to be on for most of the benefit. Recovery requires months of hard work.
Not everyone responds equally. Some people have dramatic results. Others have modest gains. Predicting individual response in advance is not yet possible.
Access is genuinely limited. The supply of research slots, the geographic concentration of programs, and the insurance barrier are real. If you're pursuing this, be prepared for a significant logistical effort.
The field is moving fast. Results that seem impossible today become standard over 5–10 years. Staying connected to research updates through the Reeve Foundation, ASIA, and clinical trial registries is worthwhile.
Active Clinical Trials (2025–2026)
- NCT07306052 — Epidural SCS for restoring walking in SCI — actively recruiting
- NCT06847295 — Epidural electrical stimulation for standing and walking in chronic paralysis
- NCT05433064 — SCS for SCI patients: regain walk and alleviate pain
- Guttmann NeuroRecovery (NCT06981338) — Intrathecal mesenchymal stem cells combined with transcutaneous SCS
Search clinicaltrials.gov for currently recruiting trials. New trials open regularly.
Sources & Further Reading
This page combines lived SCI experience with published clinical guidance, including:
- Spinal Cord Injury research overview — National Institute of Neurological Disorders and Stroke (NINDS)
- ClinicalTrials.gov — search active spinal cord stimulation trials
- Today's Care — Christopher & Dana Reeve Foundation
SCI.help articles are information, not medical advice. Practice varies by injury level, provider, and institution — always confirm specifics with your own care team.